# PTX-912

Source: https://onco.cc/drugs/ptx-912/  
OnCo record `ptx-912` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PTX-912 is an experimental immune-stimulating protein from Proviva Therapeutics, in phase 1 trials for advanced solid tumours.

## Summary

PTX-912 is a fusion protein (interleukin-2 prodrug) from Proviva Therapeutics. An interleukin-2 prodrug fusion protein meant to be switched on inside the tumour; Chinese financing reports describe it differently (one as immune-cell-targeted, one as a PD-1/IL-2 fusion), so no target is linked. The phase 1 study NCT06190886 is recruiting people with advanced solid tumours. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: PTX-912
- Modality: Fusion protein (interleukin-2 prodrug)
- Mechanism: An interleukin-2 prodrug fusion protein meant to be switched on inside the tumour; Chinese financing reports describe it differently (one as immune-cell-targeted, one as a PD-1/IL-2 fusion), so no target is linked.

## Sources

- PEdaily report on the Proviva Series A, March 2024: https://news.pedaily.cn/202403/530729.shtml
- ClinicalTrials.gov NCT06190886: https://clinicaltrials.gov/study/NCT06190886

## Connected records

- companies: [Proviva Therapeutics](https://onco.cc/companies/proviva-therapeutics/)
- trials: [A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct06190886/)

---
JSON: https://onco.cc/api/v1/entities/ptx-912.json